Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $252.4 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 165.76% year-over-year to $252.4 million; the TTM value through Sep 2025 reached $795.6 million, up 74.81%, while the annual FY2024 figure was $162.9 million, 5.46% up from the prior year.
  • Liabilities and Shareholders Equity reached $252.4 million in Q3 2025 per TNXP's latest filing, up from $187.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $252.4 million in Q3 2025 and bottomed at $70.3 million in Q2 2024.
  • Average Liabilities and Shareholders Equity over 3 years is $157.2 million, with a median of $159.7 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 55.99% in 2024, then surged 166.49% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $154.5 million in 2023, then increased by 5.46% to $162.9 million in 2024, then soared by 54.98% to $252.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $252.4 million in Q3 2025, $187.4 million in Q2 2025, and $192.9 million in Q1 2025.